Growth / Performance
Ipamorelin
C₃₈H₄₉N₉O₅
Key Research Findings
- Most selective GHRP studied to date — minimal effect on cortisol, prolactin, or ACTH.
- Synergistic GH release when combined with CJC-1295 (no DAC) in research protocols.
- Demonstrated bone density improvements in ovariectomised rat models via GH/IGF-1 axis.
- Does not desensitise GHRH receptors, allowing concurrent use with GHRH analogues.
Overview
Ipamorelin is a selective growth hormone secretagogue and ghrelin receptor agonist (GHSR-1a) consisting of 5 amino acids. It is studied for its highly selective GH-releasing properties, producing significant GH pulses without the concomitant cortisol, prolactin, or ACTH release seen with first-generation GHRPs.
Mechanism of Action
Ipamorelin activates the GHSR-1a (ghrelin receptor) on pituitary somatotrophs, triggering GH release via a distinct pathway from GHRH. Unlike GHRP-6, Ipamorelin does not significantly elevate cortisol or prolactin, making it a cleaner tool for GH research. It synergises with GHRH analogues for amplified GH output.
Research Effects
Selective GH Release
Extensive ResearchProduces dose-dependent GH pulses with high selectivity; unlike other GHRPs, does not raise cortisol or prolactin in research doses.
IGF-1 Increase
Extensive ResearchSecondary elevation of IGF-1 mediates anabolic, regenerative, and metabolic effects in multiple research models.
Body Composition
Moderate ResearchResearch in GH-deficient animal models demonstrates improvements in lean mass and fat mass following Ipamorelin treatment.
Bone Density
Moderate ResearchAnimal studies show enhanced bone mineral density via GH/IGF-1 pathway activation.
Research Purposes Only — All information on this page is provided for scientific research purposes only. This product is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Quick Facts
Research Status Key
Related Peptides
Growth / Performance
CJC-1295 (No DAC)
CJC-1295 without DAC (also known as Modified GRF 1–29 or Mod GRF 1–29) is a 29-amino acid analogue of growth hormone-releasing hormone (GHRH). It contains four amino acid substitutions that increase its stability and receptor affinity compared to native GHRH, while the absence of the Drug Affinity Complex (DAC) preserves a shorter, more physiological half-life.
Learn More →
Growth / Performance
GHRP-6
GHRP-6 is a first-generation synthetic hexapeptide growth hormone releasing peptide that acts as a potent agonist of the ghrelin receptor (GHSR-1a). It was among the first GHRP compounds studied and remains a reference compound for GH secretagogue research.
Learn More →
Growth / Performance
Tesamorelin
Tesamorelin is a synthetic analogue of GHRH consisting of the full 44-amino acid sequence of native GHRH modified with a trans-3-hexenoic acid group at the N-terminus, enhancing stability. It is the only FDA-approved GHRH analogue, licensed for HIV-associated lipodystrophy treatment under the name Egrifta.
Learn More →